Publications by authors named "Ghayas C Issa"

Claim this Profile
L
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with -negative B-cell/myeloid mixed phenotype acute leukemia.
Roberta S Azevedo, Wei-Ying Jen, Danielle Hammond, Fadi G Haddad, Alexis Geppner, Ghayas C Issa

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia.
Wei-Ying Jen, Guilin Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Ghayas C Issa

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia.
Hannah Goulart, Farhad Ravandi, Nicholas J Short, Nitin Jain, Naval Daver, Ghayas C Issa, Issa Khouri

JCO Precis Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi, Ghayas C Issa

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.
Jorge E Cortes, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Ghayas C Issa

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.
Kelly S Chien, Sanam Loghavi, Koji Sasaki, Deborah McCue, Naval G Daver, Ghayas C Issa

Clin Lymphoma Myeloma Leuk· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies.
Wei-Ying Jen, Sanam Loghavi, Alexandre Bazinet, Alex Bataller, Ian Bouligny, Ghayas C Issa

Am J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3 -Mutated AML.
Sankalp Arora, Sanam Loghavi, Naval Daver, Farhad Ravandi, Courtney D DiNardo, Ghayas C Issa

Am J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Strategies with Menin Inhibitors for Acute Leukemia.
Ghayas C Issa, Sheng F Cai, Alex Bataller, Hagop M Kantarjian, Eytan M Stein

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.
Reeja Raj, Samanta Catueno, Amber Gibson, David McCall, Miriam B Garcia, Ghayas C Issa

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, Xuemei Wang, Sanam Loghavi, Ghayas C Issa

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziftomenib in Relapsed or Refractory -Mutated AML.
Eunice S Wang, Pau Montesinos, James Foran, Harry Erba, Eduardo Rodríguez-Arbolí, Ghayas C Issa

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy.
Sven Turkalj, Felix A Radtke, Bilyana Stoilova, Rabea Mecklenbrauck, Angus J Groom, Ghayas C Issa

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia with t(10;17)(p15;q21)/: a subtype with minimal differentiation, CD7/CD56 expression, and generally poor outcomes in adults.
Qing Wei, Naveen Pemmaraju, Sa A Wang, Shimin Hu, Courtney DiNardo, Ghayas C Issa

Haematologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.
Wei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, Jessica K Altman, Musa Yilmaz, Ghayas C Issa

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias.
Jayastu Senapati, Marina Konopleva, Ghayas C Issa, Elias Jabbour, Tapan Kadia

J Hematol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.
Jennifer Croden, Wei-Ying Jen, Jennifer Marvin-Peek, Lianchun Xiao, Ian M Bouligny, Ghayas C Issa

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.
Nicholas J Short, Sanam Loghavi, Musa Yilmaz, Omer Karrar, Kunhwa Kim, Ghayas C Issa

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD123 expression and its correlation with mutation profile in acute myeloid leukaemia.
Roberta S Azevedo, Sa A Wang, David M Swanson, Naval G Daver, Naveen Pemmaraju, Ghayas C Issa

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.
Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, Sean M Devlin, Yanis Tazi, Ghayas C Issa

Blood Cancer Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
Courtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, Koichi Takahashi, Ghayas C Issa

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.
Jayastu Senapati, Hagop M Kantarjian, Tapan M Kadia, Jeannot Kekedjian, Gautam Borthakur, Ghayas C Issa

Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.
Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, Indraneel Deshmukh, Jayastu Senapati, Ghayas C Issa

Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm.
Fadi G Haddad, Jennifer Croden, Koji Sasaki, Ghayas C Issa, Naveen Pemmaraju

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of chronic myeloid leukemia in 2025.
Hagop Kantarjian, Massimo Breccia, Fadi G Haddad, Rüdiger Hehlmann, Ghayas C Issa

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis